Novartis' Elidel, Fujisawa's Protopic To Add "Black Box" On Cancer Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis expects labeling negotiations will begin within the next few weeks and says a "black box" is unjustified. A medication guide will also be required for the eczema treatments, FDA says.